作者:Mariana C. F. C. B. Damião、Kerly F. M. Pasqualoto、Adilson K. Ferreira、Sarah F. Teixeira、Ricardo A. Azevedo、José A. M. Barbuto、Fanny Palace-Berl、Gilberto C. Franchi-Junior、Alexandre E. Nowill、Maurício T. Tavares、Roberto Parise-Filho
DOI:10.1002/ardp.201400233
日期:2014.12
A novel class of benzo[d][1,3]dioxol‐5‐ylmethyl alkyl/aryl amide and ester analogues of capsaicin were designed, synthesized, and evaluated for their cytotoxic activity against human and murine cancer cell lines (B16F10, SK‐MEL‐28, NCI‐H1299, NCI‐H460, SK‐BR‐3, and MDA‐MB‐231) and human lung fibroblasts (MRC‐5). Three compounds (5f, 6c, and 6e) selectively inhibited the growth of aggressive cancer
Oxidative activation of dihydropyridine amides to reactive acyl donors
作者:Erik Daa Funder、Julie B. Trads、Kurt V. Gothelf
DOI:10.1039/c4ob01931h
日期:——
4-dihydropyridine (DHP) are activated by oxidation for acyltransfer to amines, alcohols and thiols. In the reduced form the DHP amide is stable towards reaction with amines at room temperature. However, upon oxidation with DDQ the acyl donor is activated via a proposed pyridinium intermediate. The activated intermediate reacts with various nucleophiles to give amides, esters, and thio-esters in moderate
Mechanism of the copper mediated oxidation of primary aliphatic amines by the cu0 / O2 / acetic acid system in acetonitrile
作者:Patrice Capdevielle、André Lavigne、Michel Maumy
DOI:10.1016/s0040-4020(01)88376-9
日期:1990.1
Primaryaliphaticamines are oxidized to aldehydes by the Cu0/O2/ AcOH system in acetonitrile. Kinetic measurements, particularly deuterium isotope effects studies, give support to the existence of a Cu(III) strong oxidant intermediate species in contrast with the Cu(I) O2/pyridine oxidant system in which Cu(II) has the major role.
脂肪族伯胺被乙腈中的Cu 0 / O 2 / AcOH系统氧化为醛。动力学测量,特别是氘同位素效应研究,与其中Cu(II)起主要作用的Cu(I)O 2 /吡啶氧化剂体系形成对比,支持了Cu(III)强氧化剂中间物种的存在。
ALPHA HELIX MIMETICS AND METHODS RELATING THERETO
申请人:Odagami Takenao
公开号:US20120088770A1
公开(公告)日:2012-04-12
Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.